Fosamax Related Published Studies
Well-designed clinical trials related to Fosamax (Alendronate)
A randomized, double blind, placebo-controlled trial of alendronate treatment for
fibrous dysplasia of bone. [2014]
Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal
Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical
trial. [2013]
Comparing tolerability and efficacy of generic versus brand alendronate: a
randomized clinical study in postmenopausal women with a recent fracture. [2013]
Effects of adding alendronate to ongoing hormone therapy on bone mineral density
in postmenopausal Korean women: a randomized, double-blind, placebo-controlled
clinical trial. [2013]
Targeted anti-inflammatory systemic therapy for restenosis: the Biorest Liposomal
Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical
trial. [2013]
Alendronate and atrial fibrillation: a meta-analysis of randomized
placebo-controlled clinical trials. [2012]
Prevention of Glucocorticoid-Induced Osteoporosis in Immunobullous Diseases With Alendronate: A Randomized, Double-blind, Placebo-Controlled Study. [2011.11.21]
Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis. [2011.10]
Effect of alendronate and vitamin D on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women. [2011.08]
A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty. [2011.07.06]
Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02. [2011.06]
Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. [2011.06]
Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis. [2011.06]
"Clinical Efficacy Of 1% Alendronate Gel in Adjunct to Mechanotherapy in the Treatment of Aggressive Periodontitis - A Randomized Controlled Clinical Trial" [2011.05.24]
"Clinical Efficacy of 1% Alendronate Gel as Local Drug Delivery System in the Treatment of Chronic Periodontitis - A Randomized Controlled Clinical Trial" [2011.05.04]
Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial. [2011.04]
Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. [2011.03.03]
Longitudinal evaluation of the effects of alendronate on MRI bone microarchitecture in postmenopausal osteopenic women. [2011.03.01]
Effect of oral phosphate and alendronate on bone mineral density when given as adjunctive therapy to growth hormone replacement in adult growth hormone deficiency. [2011.03]
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. [2011.02]
An open-label trial comparing alendronate and alphacalcidol in reducing falls and hip fractures in disabled stroke patients. [2011.01]
The cost effectiveness of a randomized controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate. [2011.01]
The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosis. [2011]
A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. [2010.12]
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. [2010.10]
Alendronate reduces osteoclast precursors in osteoporosis. [2010.10]
Effect of alendronate on pseudomembrane cytokine expression in patients with aseptic osteolysis. [2010.09]
Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. [2010.08]
The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study. [2010.08]
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. [2010.08]
Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. [2010.07]
High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial. [2010.05]
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. [2010.05]
The effects of weekly alendronate therapy in Taiwanese males with osteoporosis. [2010.05]
Alendronate improves QOL of postmenopausal women with osteoporosis. [2010.04.26]
Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. [2010.04]
Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. [2010.04]
Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. [2010.04]
Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. [2010.01]
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. [2010.01]
Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX). [2010.01]
Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty - a 5-year follow-up of 16 patients. [2010]
Efficacy of continued alendronate for fractures in women with and without
prevalent vertebral fracture: the FLEX trial. [2010]
Bone formation markers in patients with glucocorticoid-induced osteoporosis
treated with teriparatide or alendronate. [2010]
Effects of denosumab on bone mineral density and bone turnover in postmenopausal
women transitioning from alendronate therapy. [2010]
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. [2009.11]
Alendronate therapy in men with primary hyperparathyroidism. [2009.11]
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. [2009.10]
Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. [2009.08.31]
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. [2009.08]
Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study. [2009.08]
Vitamin D insufficiency does not affect response of bone mineral density to alendronate. [2009.07]
[Meta-analysis of alendronate preventing hip fracture risk of postmenopausal women] [2009.06.16]
A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. [2009.06]
Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. [2009.06]
Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers. [2009.05]
Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. [2009.05]
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. [2009.04]
Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial. [2009.04]
Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis. [2009.02.15]
Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. [2009.02]
Once-weekly oral medication with alendronate does not prevent migration of knee prostheses: A double-blind randomized RSA study. [2009.02]
Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. [2009.01]
Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts. [2009.01]
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. [2009.01]
The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis. [2009]
Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance. [2009]
Peripheral quantitative computed tomography is useful to monitor response to alendronate therapy in postmenopausal women. [2009]
Two-way crossover bioequivalence study of alendronate sodium tablets in healthy, non-smoking male volunteers under fasted conditions. [2009]
Truncated area under the urinary excretion rate curve in the evaluation of alendronate bioequivalence after a single dose in healthy volunteers. [2009]
Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. [2008.12.15]
Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. [2008.12]
Alendronate is effective to treat bone loss in renal transplantation recipients. [2008.12]
A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. [2008.12]
Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. [2008.12]
Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. [2008.11]
Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. [2008.11]
Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). [2008.10]
The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. [2008.10]
Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. [2008.09.20]
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. [2008.09.20]
Treatment of osteonecrosis of the hip: comparison of extracorporeal shockwave with shockwave and alendronate. [2008.09]
Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial). [2008.07.18]
[Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases] [2008.07.15]
Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. [2008.07]
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. [2008.07]
Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. [2008.06.07]
Alendronate/vitamin D(3) 70 mg/2800 IU with and without additional 2800 IU vitamin D(3) for osteoporosis: Results from the 24-week extension of a 15-week randomized, controlled trial. [2008.05.15]
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). [2008.05]
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. [2008.02.29]
The effect of alendronate on progression of spinal osteophytes and disc space narrowing. [2008.02.14]
Alendronate decreases TRACP 5b activity in osteoarthritic bone. [2008.01.23]
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. [2008.01]
Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K(2) in postmenopausal women. [2008]
Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. [2008]
Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol. [2008]
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. [2007.11.30]
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. [2007.11.15]
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. [2007.07]
Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. [2007.06]
Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. [2007.05]
|
